Chimerix Inc

Most Recent

  • uploads///Graph Part  Dec
    Company & Industry Overviews

    Chimerix Falls 80% following Phase 3 Trial of Brincidofovir

    Chimerix closed at $6.62, and its market-cap fell from $1.6 billion to $305 million on December 28, 2015.

    By Peter Neil
  • uploads///pills _
    Company & Industry Overviews

    ContraVir Stock Rose on Clinical Trial Progress Report

    ContraVir Pharmaceuticals is focused on the development of antiviral therapies with a special focus on the development of anti-HBV therapies.

    By Daniel Collins
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.